We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a win for Allergan, the U.S. Court of Appeals for the Federal Circuit upheld a federal court ruling blocking Sandoz’s proposed generic of Allergan’s eye drops Combigan (brimodine/timolol). Read More
The Patent Trial and Appeal Board (PTAB) said it’s opening an inter partes review (IPR) of patents covering Alexion Pharmaceuticals’ immunosuppressive drug Soliris (eculizumab), following a petition by Amgen. Read More
PhRMA said it “strongly encourages” the FDA’s new “integrated review process,” which combines assessments by the agency’s different disciplines into a single document for new drug applications and efficacy supplements. Read More
The court ruled that the state “met its burden” in proving that J&J’s misleading marketing and promotion of opioids caused the state’s incurred costs. Read More